Cargando…

Comparative Efficacy of Early COVID-19 Monoclonal Antibody Therapies: A Retrospective Analysis

BACKGROUND: Bamlanivimab and casirivimab/imdevimab are monoclonal antibody (mAb) treatments used for mild to moderate coronavirus disease 2019 (COVID-19) in high-risk patients. To date, there are few data summarizing real-world evidence comparing the 2 mAbs. Additionally, there are insufficient data...

Descripción completa

Detalles Bibliográficos
Autores principales:	San Filippo, Savanna, Crovetto, Brynna, Bucek, John, Nahass, Ronald G, Milano, Marc, Brunetti, Luigi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Major Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8923391/ https://www.ncbi.nlm.nih.gov/pubmed/35299987 http://dx.doi.org/10.1093/ofid/ofac080

Ejemplares similares

512. Does Time From COVID-19 Symptom Onset to Administration of Anti-spike Protein Monoclonal Antibody Predict Response?
por: SanFilippo, Savanna, et al.
Publicado: (2021)

Vancomycin area under the curve versus trough only guided dosing and the risk of acute kidney injury: Systematic review and meta‐analysis
por: Abdelmessih, Emily, et al.
Publicado: (2022)

The Association of Serotonin Toxicity with Combination Linezolid–Serotonergic Agent Therapy: A Systematic Review and Meta-Analysis
por: SanFilippo, Savanna, et al.
Publicado: (2023)

Real-world Effectiveness and Tolerability of Monoclonal Antibody Therapy for Ambulatory Patients With Early COVID-19
por: Webb, Brandon J, et al.
Publicado: (2021)

Monoclonal Antibody Therapy for COVID-19 in Solid Organ Transplant Recipients
por: Yetmar, Zachary A, et al.
Publicado: (2021)

Effectiveness of Severe Acute Respiratory Syndrome Coronavirus 2 Monoclonal Antibody Infusions in High-Risk Outpatients
por: Piccicacco, Nicholas, et al.
Publicado: (2021)

Establishment of Monoclonal Antibody Standards for Quantitative Serological Diagnosis of SARS-CoV-2 in Low-Incidence Settings
por: Thomas, Archana, et al.
Publicado: (2021)

Real-world Effect of Monoclonal Antibody Treatment in COVID-19 Patients in a Diverse Population in the United States
por: Rainwater-Lovett, Kaitlin, et al.
Publicado: (2021)

Prototype Pathogen Approach for Vaccine and Monoclonal Antibody Development: A Critical Component of the NIAID Plan for Pandemic Preparedness
por: Cassetti, M Cristina, et al.
Publicado: (2022)

Modeling the Impact of a Highly Potent Plasmodium falciparum Transmission-Blocking Monoclonal Antibody in Areas of Seasonal Malaria Transmission
por: Challenger, Joseph D, et al.
Publicado: (2023)

Safety and Pharmacokinetics of Monoclonal Antibodies VRC07-523LS and PGT121 Administered Subcutaneously for Human Immunodeficiency Virus Prevention
por: Mahomed, Sharana, et al.
Publicado: (2022)

Safety and Effectiveness of High-Dose Cefazolin in Patients With High Body Weight: A Retrospective Cohort Study
por: Ryu, HaYoung, et al.
Publicado: (2022)

Real-world Assessment of 2879 COVID-19 Patients Treated With Monoclonal Antibody Therapy: A Propensity Score–Matched Cohort Study
por: Cooper, Megan H, et al.
Publicado: (2021)

Impact of Bamlanivimab Monoclonal Antibody Treatment on Hospitalization and Mortality Among Nonhospitalized Adults With Severe Acute Respiratory Syndrome Coronavirus 2 Infection
por: Bariola, J Ryan, et al.
Publicado: (2021)

Randomized Clinical Trial to Assess the Impact of the Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01 on HIV-1 Persistence in Individuals on Effective ART
por: Riddler, Sharon A, et al.
Publicado: (2018)

Performance of a Triage Protocol for Monoclonal Antibodies in a Mixed Vaccinated and Unvaccinated Cohort of COVID-19 Patients Treated With Intravenous Infusion or Subcutaneous Injection
por: Rubin, Emily B, et al.
Publicado: (2022)

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of the Monoclonal Antibody MHAA4549A in Patients With Acute Uncomplicated Influenza A Infection
por: Lim, Jeremy J, et al.
Publicado: (2021)

Cumulative Incidence and Relative Risk of Infection in Patients With Multiple Myeloma Treated With Anti-CD38 Monoclonal Antibody-Based Regimens: A Systematic Review and Meta-analysis
por: Vassilopoulos, Stephanos, et al.
Publicado: (2022)

Safety, Tolerability and Pharmacokinetics of Half-Life Extended Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Monoclonal Antibodies AZD7442 (Tixagevimab-Cilgavimab) in Healthy Adults
por: Forte-Soto, Pablo, et al.
Publicado: (2023)

Impact of tocilizumab administration on mortality in severe COVID-19
por: Tsai, Andrew, et al.
Publicado: (2020)

Impact of Hydroxychloroquine on Mortality in Hospitalized Patients with COVID-19: Systematic Review and Meta-Analysis
por: Hong, Thomas S., et al.
Publicado: (2020)

Escape From Monoclonal Antibody Neutralization Affects Henipavirus Fitness In Vitro and In Vivo
por: Borisevich, Viktoriya, et al.
Publicado: (2016)

Effectiveness of Casirivimab-Imdevimab Monoclonal Antibody Treatment Among High-Risk Patients With Severe Acute Respiratory Syndrome Coronavirus 2 B.1.617.2 (Delta Variant) Infection
por: Al-Obaidi, Mohanad M, et al.
Publicado: (2022)

Comparative efficacy of hand hygiene agents in the reduction of bacteria and viruses
por: Sickbert-Bennett, Emily E., et al.
Publicado: (2005)

Difficulties of Identifying the Early HIV Antibody Seroconversion Period Depending on the Confirmatory Assay
por: Stefic, Karl, et al.
Publicado: (2020)

Human Monoclonal Antibody Cocktail for the Treatment or Prophylaxis of Middle East Respiratory Syndrome Coronavirus
por: Sivapalasingam, Sumathi, et al.
Publicado: (2021)

Nasal Spray of Neutralizing Monoclonal Antibody 35B5 Confers Potential Prophylaxis Against Severe Acute Respiratory Syndrome Coronavirus 2 Variants of Concern: A Small-Scale Clinical Trial
por: Lin, Yao, et al.
Publicado: (2022)

Immunological Characterization and Neutralizing Ability of Monoclonal Antibodies Directed Against Botulinum Neurotoxin Type H
por: Fan, Yongfeng, et al.
Publicado: (2016)

Comparison of Antibody Responses and Parasite Clearance in Artemisinin Therapeutic Efficacy Studies in the Democratic Republic of Congo and Asia
por: Cutts, Julia C, et al.
Publicado: (2022)

Antibody Correlates of Protection From Severe Respiratory Syncytial Virus Disease in a Vaccine Efficacy Trial
por: Fong, Youyi, et al.
Publicado: (2023)

Severe Acute Respiratory Syndrome Coronavirus 2 Monoclonal Antibody Combination Therapy in Patients With Coronavirus Disease 2019 and Primary Antibody Deficiency
por: Pulvirenti, Federica, et al.
Publicado: (2021)

Cross-sectional Characterization of SARS-CoV-2 Antibody Levels and Decay Rates Following Infection of Unvaccinated Elderly Individuals
por: Whelan, Marilyn, et al.
Publicado: (2023)

Engineering, Expression in Transgenic Plants and Characterisation of E559, a Rabies Virus-Neutralising Monoclonal Antibody
por: van Dolleweerd, Craig J., et al.
Publicado: (2014)

Early hematological parameters as predictors for outcomes in children with dengue in northern India: A retrospective analysis
por: Nandwani, Sumi, et al.
Publicado: (2021)

Brucellar, Pyogenic, and Tuberculous Spondylodiscitis at Tertiary Hospitals in Saudi Arabia: A Comparative Retrospective Cohort Study
por: AlQahtani, Hajar, et al.
Publicado: (2023)

Early Antimicrobial De-escalation and Stewardship in Adult Hematopoietic Stem Cell Transplantation Recipients: Retrospective Review
por: Snyder, Matthew, et al.
Publicado: (2017)

Increased Breadth of Group A Streptococcus Antibody Responses in Children With Acute Rheumatic Fever Compared to Precursor Pharyngitis and Skin Infections( )
por: Whitcombe, Alana L, et al.
Publicado: (2022)

Persistence of Neutralizing Antibodies and Clinical Protection up to 12 Months After Severe Acute Respiratory Syndrome Coronavirus 2 Infection in the Elderly
por: Collarino, Rocco, et al.
Publicado: (2022)

Antibody Responses After Analytic Treatment Interruption in Human Immunodeficiency Virus-1-Infected Individuals on Early Initiated Antiretroviral Therapy
por: Stephenson, Kathryn E., et al.
Publicado: (2016)

Escape from Human Monoclonal Antibody Neutralization Affects In Vitro and In Vivo Fitness of Severe Acute Respiratory Syndrome Coronavirus
por: Rockx, Barry, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_tpvtk167e1rbi7gl3dpnghrrui